Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)

NCT00101985 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

741

Enrollment

INDUSTRY

Sponsor class

Conditions

Irritable Colon

Interventions

DRUG: talnetant

Sponsor

GlaxoSmithKline